A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Smoking Cessation

Treatments

Drug: CP-526,555 (varenicline)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00150241
A3051002

Details and patient eligibility

About

The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects must have smoked on average of at least ten cigarettes per day during the past year
  • Subjects must have no period of abstinence greater than three months in the past year

Exclusion criteria

  • Subjects with any history of cardiovascular disease
  • Myocardial infarction
  • Significant arrhythmias
  • Poorly controlled hypertension

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems